Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer
{{output}}
Objective: The aim of the study was to assess whether immune-related adverse events (irAE) act as predictive biomarkers of response to immune checkpoint inhibitors in non-small-cell lung cancer in real-life practice. ... ...
